Clinical Evaluation of a Thiamidol-based Cream for Treatment of Periorbital Hyperpigmentation
SKIN The Journal of Cutaneous Medicine · 14.07.2026 · 10 (4) · s797
DOI: 10.25251/96p2j829 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 14.07.2026. Verfasst von Seemal Desai und 2 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Periorbital hyperpigmentation caused by various factors including genetics, photodamage, sleep deprivation, and allergies are a visible concern for many patients. Additional pigmentation and shadows may be due to skin laxity and wrinkles, as well as thin, translucent skin. Periorbital hyperpigmentation can present as brown pigmented and blue vascular types, with most patients presenting with both types. Thiamidol is a potent inhibitor of human tyrosinase and has been shown to be effective in management of facial hyperpigmentation.
Objectives
These studies aimed to evaluate the efficacy and tolerability of a Thiamidol-based cream with skin strengthening active oligonucleotides and hyaluronic acid in the reduction of periorbital hyperpigmentation.
Methods
A split-face, clinical study of females (n=33, Fitzpatrick Skin Types II-VI) with vascular, pigmented, or mixed periorbital hyperpigmentation was performed with twice-daily application of a Thiamidol-based under eye cream vs untreated control for 12 weeks to evaluate reduction of pigmentation. Outcome evaluations included expert clinical grading, self-grading, and a self-assessment questionnaire. Tolerability was evaluated in females (n=33, 65.7% sensitive skin) that applied the Thiamidol-based under eye cream twice daily to face for 2 weeks. Dermatologic and ophthalmologic assessments were conducted at baseline and study end. Female volunteers (n=120) were included in a 4-week product-in-use study, with a self-assessment questionnaire on product performance at end of Week 4.
Results
Improvement in periorbital hyperpigmentation was measured in 63.6% of subjects after 12 weeks of twice daily application, with improvements in hyperpigmentation, skin evenness and radiance observed as early as Week 2 and continuing to improve through Week 12. Very good tolerability was demonstrated following both dermatologic and ophthalmologic assessment, even for subjects with sensitive skin. After 4 weeks of product use, 98% of subjects confirmed that the Thiamidol-based cream had a long-lasting reduction of dark circles, reduced wrinkles and lines, and provided radiant skin.
Conclusion
Thiamidol, when combined with skin strengthening active oligonucleotides and hyaluronic acid, can be an effective treatment option for patients with periorbital hyperpigmentation.
Zitieren
APA
Desai, S., Elbuluk, N., & Lain, E. (2026). Clinical Evaluation of a Thiamidol-based Cream for Treatment of Periorbital Hyperpigmentation. SKIN The Journal of Cutaneous Medicine, 10(4), s797. https://doi.org/10.25251/96p2j829
Vancouver
Desai S, Elbuluk N, Lain E. Clinical Evaluation of a Thiamidol-based Cream for Treatment of Periorbital Hyperpigmentation. SKIN The Journal of Cutaneous Medicine. 2026;10(4):s797. doi:10.25251/96p2j829
BibTeX
@article{Desai2026,
author = {Desai, Seemal and Elbuluk, Nada and Lain, Edward},
title = {Clinical Evaluation of a Thiamidol-based Cream for Treatment of Periorbital Hyperpigmentation},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {4},
pages = {s797},
doi = {10.25251/96p2j829}
}
EUVIMED